Psychiatry · Medical Literature
Effect of continuation treatment on health-related quality of life in remitted psychotic depression.
Abstract
Continuation treatment with sertraline plus olanzapine is associated with lower risk of relapse of remitted psychotic depression than sertraline plus placebo. We examined the effect of continuation pharmacotherapy on health-related quality of life (HRQOL) in remitted psychotic depression. One hundred and twenty-six men and women, aged 18 to 85 years, who had achieved sustained remission of psychotic depression with open-label treatment with sertraline plus olanzapine were randomized to continue sertraline plus either olanzapine or placebo. HRQOL was measured with the 36-item Short Form Health Survey (SF-36) at randomization baseline and study termination. The primary outcome was change in each of the eight SF-36 domains. Linear regression examined the relationship between randomized treatment and change in SF-36 domain scores. Sertraline plus olanzapine was associated with better outcomes in the Role Emotional (RE) and Mental Health (MH) domains than sertraline plus placebo. Relapse was associated with marked decline in both RE and MH scores. RE and MH scores at study termination were more than two standard deviations below the population mean in approximately one quarter of participants in the sertraline plus placebo group. In individuals with remitted psychotic depression, continuation treatment with sertraline plus olanzapine was associated with better outcomes in HRQOL domains directly relevant to mental health than treatment with sertraline plus placebo. These findings suggest that the benefit of sertraline plus olanzapine in preventing relapse of psychotic depression is associated with benefit in HRQOL.
Clinical relevance
In patients with remitted psychotic depression, does continuation treatment with sertraline plus olanzapine, compared with sertraline plus placebo, produce superior health-related quality of life (HRQOL) outcomes over the course of a randomized continuation trial? __SNAPSHOT__ {"studyDesign":"Randomized controlled trial (continuation phase; double-blind); secondary HRQOL analysis of the STOP-PD II trial","setting":"Multiple academic psychiatric sites in the United States and Canada (STOP-PD II Study Group)","sampleSize":"n = 126 (intervention: sertraline + olanzapine; comparator: sertraline + placebo; exact per-group allocation not reported in the abstract)","population":"Men and women aged 18–85 years who had achieved sustained remission of psychotic depression (major depressive disorder with psychotic features) following open-label acute treatment with sertraline plus olanzapine","intervention":"Continuation sertraline plus olanzapine","comparator":"Continuation sertraline plus placebo (olanzapine discontinued)","primaryOutcome":"Change from randomization baseline to study termination in each of the eight SF-36 (36-item Short Form Health Survey) domain scores, analyzed via linear regression","followUp":"Not reported explicitly in the abstract; study termination was the endpoint for SF-36 assessment","fundingSource":"Government (NIMH grants to multiple investigators, per author disclosures); one author (Alexopoulos) also reported advisory board and speakers bureau relationships with Otsuka"}
Key findings
Among 126 participants with remitted psychotic depression, continuation sertraline plus olanzapine was associated with significantly better outcomes than sertraline plus placebo in two of the eight SF-36 domains: Role Emotional (RE) and Mental Health (MH). The remaining six SF-36 domains (Physical Functioning, Role Physical, Bodily Pain, General Health, Vitality, Social Functioning) did not demonstrate a significant treatment group difference based on the abstract. Specific between-group effect sizes, p-values, and confidence intervals for the RE and MH domain comparisons were not reported in the abstract. Relapse was identified as a strong mediating factor: patients who relapsed experienced marked declines in both RE and MH scores. Approximately one quarter of patients had RE and MH scores at study termination that were more than two standard deviations below the population mean, indicating a subset with severely impaired mental HRQOL at trial end. No adverse event data or NNT/NNH were reported in the abstract. No independently calculated values are included due to insufficient raw data.
Practice implications
This study establishes that in remitted psychotic depression, the relapse-prevention benefit of olanzapine continuation (already demonstrated as the primary outcome of STOP-PD II) extends meaningfully to the mental health domains of HRQOL, specifically Role Emotional functioning and Mental Health. This is clinically important because it links pharmacological efficacy to a patient-centered outcome. However, the benefit was restricted to mental health domains; physical HRQOL domains were not significantly affected by treatment assignment, suggesting that olanzapine's known metabolic and sedative burden may attenuate broader quality-of-life gains. The finding that relapse was associated with marked HRQOL decline reinforces relapse prevention as the key mechanism linking treatment choice to patient welfare. Caution is warranted: this is a secondary analysis of a trial powered for a relapse outcome, not for SF-36 domain comparisons, raising the possibility of type I error across eight simultaneous domain tests. The wide age range (18–85 years) may limit generalizability to specific age subgroups (e.g., older adults with comorbid medical illness). Patients who never achieved remission on sertraline plus olanzapine were not represented. Only the abstract was available for review; specific statistical values, per-group sample sizes, and sensitivity analyses cannot be verified. Practice should not change solely on the basis of this secondary analysis, though it supports existing evidence favoring olanzapine continuation for relapse prevention. __LIMITATIONS__ Secondary HRQOL analysis of a trial powered for a binary relapse endpoint; risk of inflated type I error across eight simultaneous SF-36 domain comparisons without reported correction for multiple testing.,Exact per-group sample sizes, effect sizes, confidence intervals, and p-values for SF-36 domain comparisons not reported in the abstract, precluding independent assessment of magnitude or precision.,Follow-up duration not specified in the abstract, limiting appraisal of whether HRQOL changes reflect short- or long-term benefit.,Generalizability limited to patients who achieved sustained remission with open-label sertraline plus olanzapine; non-remitters and treatment-resistant patients were excluded.,Wide age range (18–85 years) without reported age-stratified HRQOL analyses may mask differential effects in younger versus older adults.,Potential confounding by relapse: the treatment-HRQOL relationship may be partially or fully mediated by relapse prevention rather than a direct pharmacodynamic effect of olanzapine on quality of life.,Olanzapine's metabolic effects (weight gain, dyslipidemia) were not discussed in the abstract in relation to physical HRQOL domains where no benefit was observed.,One investigator reported advisory board and speakers bureau relationships with Otsuka, a manufacturer of antipsychotic medications; NIMH funding reduces but does not eliminate potential for reporting bias.,Only the abstract was available; full methods, sensitivity analyses, and subgroup analyses cannot be reviewed. __BOTTOM_LINE_CATEGORY__ confirmatory __BOTTOM_LINE__ Continuation treatment with sertraline plus olanzapine in remitted psychotic depression is associated with better outcomes in Role Emotional and Mental Health domains of the SF-36 compared with sertraline plus placebo, likely mediated substantially through relapse prevention. This secondary HRQOL analysis supports, but does not independently justify, continuation of olanzapine beyond the previously established relapse-prevention indication. Clinicians should weigh these mental HRQOL benefits against olanzapine's metabolic and tolerability risks when making individualized continuation treatment decisions.